Lipopeptide antigen
Lipopeptides, conjugates of lipids and peptides, address the ineffectiveness of conventional vaccines against mutated viruses by activating human T cells, particularly CTLs, ensuring a strong immune response against both wild-type and mutated viruses.
WO2026134289A1PCT designated stage Publication Date: 2026-06-25OSAKA UNIVERSITY
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- OSAKA UNIVERSITY
- Filing Date
- 2025-12-18
- Publication Date
- 2026-06-25
Smart Images
Figure JP2025044275_25062026_PF_FP_ABST
Abstract
The present invention addresses the problem of providing: a new antigen that can also be effective against mutant viruses; and a new vaccine obtained by using said antigen. Said problem is solved by providing a lipopeptide which is obtained by conjugating a lipid and a peptide and in which the peptide has antigenicity and is represented by formula (1): a-b-c-d(-e-f)n. In the formula, n represents 0 or 1, and a-f include a specific amino acid.
Need to check novelty before this filing date? Find Prior Art